ALGS - CIK 0001799448
Aligos Therapeutics, Inc. trades as ALGS. In its fiscal 2025 annual report the company posted revenue of $2.19M, down 39.5% from the prior year and net income of -$24.19M. This page tracks Aligos Therapeutics, Inc. through 334 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -1416.2% to -1106.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Major company event | 8-K | 2026-04-21 |
The largest companies sharing Aligos Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Aligos Therapeutics, Inc. reported revenue of $2.19M for fiscal year 2025, a decrease of 39.5% year over year.
In its latest fiscal year Aligos Therapeutics, Inc. reported a net loss of $24.19M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.